A new therapy employing viruses to combat chronic infections, particularly those resistant to antibiotics, is now accessible over-the-counter in Europe. This treatment offers a potential alternative for individuals whose infections no longer respond to conventional antibiotics.
David Felstead's experience highlights the challenges faced by patients with persistent infections. For six years, he was treated for a superbug infection in his left leg. As antibiotics proved ineffective, his health deteriorated, and he faced the risk of amputation.
The therapy involves bacteriophages, which are viruses that specifically target and destroy bacteria. Unlike broad-spectrum antibiotics that can harm beneficial bacteria in the body, phage therapy is highly specific to the bacterial strain causing the infection.
As conventional antibiotics failed to clear his infection, David's medical team considered further surgeries that seemed unlikely to succeed or amputation. The availability of phage therapy in Europe presented a new option.
This development comes amid growing global concern over antibiotic resistance, a phenomenon where bacteria evolve to withstand the drugs designed to kill them, rendering treatments ineffective and posing a significant threat to public health. The World Health Organization has identified antimicrobial resistance as one of the top 10 global public health threats facing humanity. The European market's acceptance of this therapy over-the-counter suggests a potential shift in how such difficult-to-treat infections are managed.